Evofem Biosciences Inc logo

EVFM - Evofem Biosciences Inc Share Price

$2.34 -0.1  -3.7%

Last Trade - 21/09/20

Sector
Healthcare
Size
Small Cap
Market Cap £152.9m
Enterprise Value £91.4m
Revenue £n/a
Position in Universe 3781st / 6392
Bullish
Bearish
Unlock EVFM Revenue
Momentum
Relative Strength (%)
1m -27.1%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -67.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 8.35 59.7
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Evofem Biosciences Inc revenues was not reported. Net loss increased 34% to $71.8M. Higher net loss reflects Loss on issuance of financial instrument increase from $674K to $64M (expense), Stock-based Compensation in SGA increase of 67% to $6.4M (expense), General and Administrative Expense - Bal increase of 22% to $10.3M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

EVFM Revenue Unlock EVFM Revenue

Net Income

EVFM Net Income Unlock EVFM Revenue

Normalised EPS

EVFM Normalised EPS Unlock EVFM Revenue

PE Ratio Range

EVFM PE Ratio Range Unlock EVFM Revenue

Dividend Yield Range

EVFM Dividend Yield Range Unlock EVFM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
EVFM EPS Forecasts Unlock EVFM Revenue
Profile Summary

Evofem Biosciences Inc, formerly Neothetics, Inc., is a clinical-stage specialty biopharmaceutical company. The Company develops products to address unmet needs in women's sexual and reproductive health. The Company’s product Amphora, is a Multipurpose Vaginal pH Regulator (MVP-R) designed to regulate vaginal pH to within the normal range of 3.5 to 4.5 even in the presence of semen. This maintains an acidic environment which is inhospitable to sperm as well as certain viral and bacterial pathogens associated with sexually transmitted infections. Amphora is used to prevent urogenital chlamydia and gonorrhea in women. The Company is in the second Phase III clinical trial of Amphora for prevention of pregnancy (AMP002). The Company is currently designing a Phase IIb trial for its second product candidate, a MVP-R to reduce the recurrence of bacterial vaginosis.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated February 1, 2007
Public Since November 20, 2014
No. of Shareholders: 35
No. of Employees: 53
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 81,280,286
Free Float (0.0%)
Eligible for
ISAs
SIPPs
EVFM Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for EVFM
Upcoming Events for EVFM
Tuesday 22nd September, 2020
Evofem Biosciences Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual)
Wednesday 4th November, 2020 Estimate
Q3 2020 Evofem Biosciences Inc Earnings Release
Wednesday 10th March, 2021 Estimate
Q4 2020 Evofem Biosciences Inc Earnings Release
Frequently Asked Questions for Evofem Biosciences Inc
What is the Evofem Biosciences Inc share price?

As of 21/09/20, shares in Evofem Biosciences Inc are trading at $2.34, giving the company a market capitalisation of £152.9m. This share price information is delayed by 15 minutes.

How has the Evofem Biosciences Inc share price performed this year?

Shares in Evofem Biosciences Inc are currently trading at $2.34 and the price has moved by -56.76% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Evofem Biosciences Inc price has moved by -61.46% over the past year.

What are the analyst and broker recommendations for Evofem Biosciences Inc?

Of the analysts with advisory recommendations for Evofem Biosciences Inc, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Evofem Biosciences Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Evofem Biosciences Inc next release its financial results?

Evofem Biosciences Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Evofem Biosciences Inc dividend yield?

Evofem Biosciences Inc does not currently pay a dividend.

Does Evofem Biosciences Inc pay a dividend?

Evofem Biosciences Inc does not currently pay a dividend.

When does Evofem Biosciences Inc next pay dividends?

Evofem Biosciences Inc does not currently pay a dividend.

How do I buy Evofem Biosciences Inc shares?

To buy shares in Evofem Biosciences Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Evofem Biosciences Inc?

Shares in Evofem Biosciences Inc are currently trading at $2.34, giving the company a market capitalisation of £152.9m.

Where are Evofem Biosciences Inc shares listed? Where are Evofem Biosciences Inc shares listed?

Here are the trading details for Evofem Biosciences Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: EVFM
What kind of share is Evofem Biosciences Inc?

Based on an overall assessment of its quality, value and momentum, Evofem Biosciences Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Evofem Biosciences Inc share price forecast 2020?

Shares in Evofem Biosciences Inc are currently priced at $2.34. At that level they are trading at 0.291% discount to the analyst consensus target price of 0.00.

Analysts covering Evofem Biosciences Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.927 for the next financial year.

How can I tell whether the Evofem Biosciences Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Evofem Biosciences Inc. Over the past six months, the relative strength of its shares against the market has been -59.51%. At the current price of $2.34, shares in Evofem Biosciences Inc are trading at -46.06% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Evofem Biosciences Inc PE Ratio?

We were not able to find PE ratio data for Evofem Biosciences Inc.

Who are the key directors of Evofem Biosciences Inc?

Evofem Biosciences Inc's management team is headed by:

Kim Kamdar - IND
Saundra Pelletier - PRE
Justin File - CFO
Kelly Culwell - OTH
Russell Barrans - OTH
Alexander Fitzpatrick - EVP
Gillian Greer - IND
William Hall - IND
Tony O'Brien - IND
Thomas Lynch - CHM
Lisa Rarick - IND
Who are the major shareholders of Evofem Biosciences Inc?

Here are the top five shareholders of Evofem Biosciences Inc based on the size of their shareholding:

INVESCO Asset Management Limited Investment Advisor/Hedge Fund
Percentage owned: 15.59% (12.7m shares)
Invesco UK Equity High Income Mutual Fund
Percentage owned: 9.43% (7.66m shares)
Invesco UK Equity Income Fund UK Mutual Fund
Percentage owned: 5.1% (4.15m shares)
Schroder Investment Management Ltd. (SIM) Investment Advisor/Hedge Fund
Percentage owned: 3.27% (2.66m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 3.13% (2.54m shares)
Similar to EVFM
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.